Clinical consequences of analytical variance and calculation strategy in oral busulfan pharmacokinetics

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2316-2321

  Olson, Matthew T ^a   Lombardi, Lindsey ^a   Clarke, William ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Analytical variance; Busulfan; Clinical pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

BUSULFAN;

ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL EFFECTIVENESS; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; RELIABILITY;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BUSULFAN; CALIBRATION; HUMANS;

EID: 80053630530     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.08.028     Document Type: Article

References (13)

1. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989, 25:55-61.
2. McCune J.S., Gooley T., Gibbs J.P., et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 30:167-173.
3. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000, 25:925-930.
4. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997, 89:3055-3060.
5. Grochow L.B., Krivit W., Whitley C.B., Blazar B. Busulfan disposition in children. Blood 1990, 75:1723-1727.
6. Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood 1994, 84:2144-2150.
7. Gibbs J.P., Gooley T., Corneau B., et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999, 93:4436-4440.
8. McCune J.S., Holmberg L.A. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol 2009, 5:957-969.
9. Léger F., Nguyen L., Puozzo C. Exposure equivalence between IV (0.8mg/kg) and oral (1mg/kg) busulfan in adult patients. Eur J Clin Pharmacol 2009, 65:903-911.
10. Bleyzac N. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam Clin Pharmacol 2008, 22:605-608.
11. Salinger D.H., Vicini P., Blough D.K., O'Donnell P.V., Pawlikowski M.A., McCune J.S. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration. J Clin Pharmacol 2010, 50:1292-1300.
12. Kolbe K., Karstens A., Krämer I. Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules. J Oncol Pharm Pract 2010, 16:151-159.
13. Hoffer E., Akria L., Tabak A., Scherb I., Rowe J.M., Krivoy N. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation. Ther Drug Monit 2004, 26:331-335.